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How are we going to win this battle? Surely not 
 with a single magic bullet, wheter it is a gene, device 
or drug. Most important, as any battle,  
we must understand the terrain on wich it will be 
fought. 
 
Eugene Braunwald 
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RESUMO 
 
 
A necessidade de buscar novos tratamento para a Insuficiência Cardíaca (IC) crônica levanta o 
questionamento da eficácia e segurança de drogas que não foram adequadamente testadas ou que 
ainda não tiveram sua eficácia aceita pela comunidade científica. O sildenafil é um vasodilatador com 
potencial eficácia na redução da pressão sistólica da artéria pulmonar (PSAP), mas com pequenos 
estudos e sem demonstração de impacto em desfechos duros. Os diuréticos de alça são utilizados 
rotineiramente em pacientes com IC sem sinais de congestão e tal prática não está recomendada nas 
diretrizes terapêuticas, desconhecemos sua eficácia e segurança neste cenário. No intuito de elucidar 
estas questões, foram desenvolvidos I) revisão sistemática com metanálise para estudo uso de 
sildenafil. II) revisão sistemática com metanálise para estudo uso de diurético de alça, III) 
Delineamento e execução em andamento de ensaio clínico randomizado multicêntrico testando a 
retirada de diurético de alça. I e II) Métodos e resultados: Ambas revisões sistemáticas foram 
realizadas no Pubmed, Embase e Cochrane, e termos relacionados à insuficiência cardíaca crônica 
diurético de alça e sildenafil foram utilizados, respectivamente. Após avaliação de texto completo, 
apenas estudos em humanos foram incluídos na metanálise.  A droga sildenafil foi avaliada em 9 
estudos randomizados contra placebo e demonstrou redução de hospitalização (RR 0.29, 95% C.I 
0.11 to 0.78) e melhora progressiva em parâmetros funcionais e hemodinâmicos O uso de diurético 
de alça foi testado em 7 ensaios clínicos e não mostrou significância em piora da função renal, 
distúrbio eletrolítico e mudança de peso. III) Métodos e resultados: Em um estudo duplo-cego 
randomizado, de não inferioridade, multicêntrico compara-se o a segurança e tolerabilidade da 
retirada de furosemida de pacientes com IC crônica e estável com disfunção ventricular. Com início 
da coleta em setembro de 2015, até o momento 96 pacientes foram randomizados. Conclusão: 
Quanto ao sildenafil, já temos evidências que apontam para um efeito benéfico e progressivo na 
melhora da capacidade funcional, perfil hemodinâmico e redução de hospitalização em pacientes com 
IC com disfunção ventricular e pressão da artéria pulmonar elevada A recomendação para uso de 
diurético de alça em pacientes estáveis com IC permanece uma incógnita e o ensaio clínico em 
andamento nos trará uma resposta de importante impacto clínico na tomada de decisão para 
manutenção do uso de diurético. 
 
Palavras-chave: Insuficiência Cardíaca; Diuréticos; Sildenafil; Inibidores das Fosfodiesterase 5; 
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ABSTRACT 
The challenges and promises of new treatments for chronic heart failure (CHF) raises the question of 
the efficacy and safety of drugs that have not been properly tested or that have not yet had their 
efficacy accepted by the scientific community. Sildenafil is a vasodilator with potential efficacy in 
reducing pulmonary artery systolic pressure (PSAP), but with small studies and no demonstration of 
impact on hard outcomes. Routinely, Loop diuretics are used in patients with HF without signs of 
congestion and such practice is not recommended in the therapeutic guidelines, we do not know its 
efficacy and safety in this scenario. In order to elucidate these questions, I) systematic review with 
meta-analysis were developed to study the use of sildenafil. II) systematic review with meta-analysis 
to study the use of loop diuretics, III) Design and execution in progress of a multicenter randomized 
clinical trial testing for loop diuretic withdrawal. I and II) Methods and results: Both systematic 
reviews were performed in PubMed, Embase and Cochrane, and terms related to chronic diuretic 
heart failure of the loop and sildenafil were used, respectively. After full-text evaluation, only human 
studies were included in the meta-analysis. The drug sildenafil was evaluated in 9 randomized 
placebo-controlled studies and demonstrated a reduction in hospitalization (RR 0.29, 95% CI 0.11 to 
0.78) and progressive improvement in functional and hemodynamic parameters. The use of a loop 
diuretic was tested in 7 clinical trials and did not show significant deterioration in renal function, 
electrolyte disturbance and weight change. III. METHODS AND RESULTS: In a double-blind 
randomized, non-inferiority, multicenter study, the safety and tolerability of furosemide withdrawal 
from patients with chronic and stable HF with ventricular dysfunction were compared. 
Randomization started at September 2015, to the moment 96 patients were randomized. 
CONCLUSION: Regarding sildenafil, we already have evidence of a beneficial and time-related 
effect on the improvement of functional capacity, hemodynamic profile and reduction of 
hospitalization in patients with HF with ventricular dysfunction and elevated pulmonary artery 
pressure. The recommendation for the use of a loop diuretic in stable patients with HF remains an 
unknown and the ongoing clinical trial will provide us with an important clinical impact response in 
the decision making to maintain the use of diuretics. 
 
Keywords: Heart Failure; Diuretics; Sildenafil Citrate; Phosphodiesterase Inhibitors 5 
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1. MARCO TEÓRICO 
 
1.1 INSUFICIÊNCIA CARDÍACA 
A constante crescente prevalência da insuficiência cardíaca (IC) está atingindo proporções 
epidêmicas. Com o envelhecimento da população e a melhora no tratamento das doenças 
cardiovasculares, a tendência é de que os números sigam aumentando. Entre os idosos de países 
ocidentais,  já é a principal causa de admissão hospitalar e atinge cerca de 5% da população 
mundial(1). No cenário brasileiro, no período de 2004 a 2014, foram registrados 301.136 mortes(2), 
sendo que a enfermidade é a principal causa de reospitalização, com elevada mortalidade em 5 anos, 
despendendo cerca de 5% do orçamento destinado aos gastos com saúde(3) 
A IC é uma doença crônica e o tratamento envolve diversas medicações. Portanto, a 
necessidade de um modelo de acompanhamento longitudinal e multidisciplinar é imprescindível e 
tem se mostrado como uma das intervenções de maior eficácia. O manejo da IC teve enormes avanços 
nos últimos 30 anos e esses, nos fazem questionar a eficácia de antigas drogas, como furosemida e 
digoxina. Tais medicações foram implementadas no arsenal terapêutico sem estudos com 
delineamentos adequados e foram testadas em pacientes virgens de outros tratamentos. 
As inovações não apenas nos fazem questionar o velho, o antigo tratamento, mas trazem um 
melhor entendimento sobre a patofisiologia e isso nos faz reconhecer fatores que podem estar 
associados com a piora e com a progressão da doença.  
 
1.1.1 HIPERTENSÃO PULMONAR GRUPO 2 
 
A hipertensão arterial pulmonar (HAP) começou a ser estudada devido à sua prevalência entre 
os pacientes com disfunção ventricular, atingindo entre 49% a 79% dos pacientes com IC com 
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disfunção ventricular(4). O desenvolvimento da HAP é consequência do prejudicado relaxamento e 
distensibilidade do ventrículo esquerdo(5). Independentemente da etiologia da disfunção ventricular 
esquerda, a presença de pressões elevadas na artéria pulmonar está associada com maior gravidade 
dos sintomas, baixa tolerância ao exercício e pior prognóstico(6).  
Define-se hipertensão pulmonar (HP) quando a pressão da artéria pulmonar média (PAPm) 
atinge valores iguais ou superiores a 25 mmHg em repouso, mensurada por cateterismo da artéria 
pulmonar. A PAPm pode elevar-se devido ao aumento da pressão de oclusão da artéria pulmonar 
(Poap), devido ao fenômeno hiperdinâmico, pelo aumento do débito cardíaco ou por hiper-resistência, 
devido ao aumento da resistência vascular pulmonar (RVP). Estabelece-se hipertensão venosa 
pulmonar quando a Paop >15mmHg, pós-capilar devido à doença cardíaca esquerda (7). A 
classificação de Dana Point (8), divide-se em cinco categorias, a HP relacionada com doença cardíaca 
esquerda é classificada como grupo 2 e tem, na hipertensão venosa pulmonar, o gatilho de sua 
fisiopatogenia. 
O aumento da pressão no átrio esquerdo e de forma retrógrada e passiva eleva a pressão da 
artéria pulmonar média. Inicialmente a resistência vascular pulmonar está normal, no entanto, o 
estresse contínuo na vasculatura pulmonar e o componente pós capilar, congestão venosa, levam ao 
barotrauma da microcirculação. Este fenômeno promove o remodelamento estrutural das artérias da 
vasculatura pulmonar, com proliferação de miofibroblastos, com deposição de fibrose e matriz 
extracelular, que passam a formar o componente pré-capilar da hipertensão pulmonar do grupo 2 (6). 
A disfunção endotelial pode levar ao desequilíbrio das substâncias vasodilatadoras e vasoconstritoras 
nas artérias da pequena vasculatura pulmonar, desencadeando um aumento de endotelina-1, redução 
de óxido nítrico circulante, dessensibilização dos receptores de peptídeos natriuréticos e ativação da 
cadeia inflamatória.  
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Apesar da hipertensão pulmonar ser um processo multifatorial e progressivo, a observação da 
redução da pressão sistólica da artéria pulmonar e a manutenção de sua normalização em pacientes 
submetidos ao implante de dispositivos de assistência ventricular esquerda indicam que essa alteração 
na circulação pulmonar pode ser reversível (9). 
Está claro que alterações na hemodinâmica pulmonar ocorrem desde estágios iniciais da 
insuficiência cardíaca e que devemos considerar a redução da pressão sistólica da artéria pulmonar e 
a reversibilidade desse ciclo nocivo como um alvo terapêutico naqueles pacientes com insuficiência 
crônica e manejo otimizado. 
 
1.1.2 SILDENAFIL E INIBIDORES DA FOSFODIESTERASE-5 
 
 Sildenafil é um inibidor seletivo da fosdiesterase-5, a principal isoenzima das fosfodiesterases 
responsável pela hidrólise intracelular da monofosfato de guanosine cíclica (cGMP) na vasculatura 
pulmonar. Altas concentrações de fosfodiesterase-5 são encontradas nas células do músculo liso dos 
vasos pulmonares e na vasculatura sistêmica, tanto venosa, quanto arterial periférica. Inibição da 
fosfodiesterase-5 prolonga a ação do cGMP, que é o segundo mensageiro na cascata de liberação do 
óxido nítrico. Isto provoca o aumento da disponibilidade do óxido nítrico no leito vascular, causando 
relaxamento das células musculares lisas e, consequentemente, vasodilatação (10,11).Tal mecanismo 
justifica o uso do sildenafil no tratamento da disfunção erétil, distúrbio no qual a droga faz parte da 
primeira linha de tratamento (12,13) 
A indicação de sildenafil na terapêutica da hipertensão arterial pulmonar primária está bem 
estabelecida, mostrando benefícios na melhora da capacidade funcional e redução da pressão média 
da artéria pulmonar (14). No entanto, estudos demonstrando a eficácia do sildenafil em pacientes com 
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IC são limitados e com amostra pequena, com desfechos restritos à avaliação hemodinâmica, sem 
dados robustos sobre o benefício clínico desta terapia (15), o que tampouco justifica o uso de 
sildenafil na insuficiência cardíaca, independentemente da fração de ejeção do ventrículo esquerdo e 
classe funcional (16,17). 
O Sildenafil tem se mostrado uma droga promissora quando se almeja a vasodilatação do 
sistema arterial. Alguns estudos que avaliaram o efeito do sildenafil em pacientes hipertensos com 
disfunção diastólica mostraram, por avaliação ecocardiográfica, a indução do relaxamento ventricular 
esquerdo e a redução de NT-proBNP (18). 
 O estudo RELAX é o maior ensaio clinico randomizado, multicêntrico, realizado com 
sildenafil em pacientes com fração de ejeção preservada num seguimento de 24 semanas. Embora 
tenha sido muito esperado, seus resultados não mostraram benefício na melhora da capacidade de 
exercício ou em desfechos secundários como mortalidade e hospitalização (16). No entanto, estão 
sendo feitas diversas análises de subgrupos do estudo RELAX, na tentativa de identificar possíveis 
preditores de resposta ao sildenafil. Recentemente, uma subanálise demonstrou que o grupo de 
pacientes com fibrilação atrial apresentou pior performance ao exercício físico (19), assim como 
Borlaug et al. Subanálise do estudo RELAX evidenciou que ocorre uma modesta redução da 
contratilidade miocárdica agudamente após o uso de sildenafil e sugere que o efeito do sildenafil é 
benéfico na vasculatura sistêmica, porém questiona seu impacto no remodelamento ventricular (20). 
Uma das hipóteses para a ausência de benefício nos pacientes com fração de ejeção preservada 
estaria relacionada com o grau de disfunção endotelial. Especula-se que pacientes com maior 
acometimento e doença do endotélio apresentariam maior benefício com o uso do sildenafil, visto 
que seu principal efeito é na vasodilatação arterial, aumento do óxido nítrico circulante (21). 
 
1.1.3 DIURÉTICOS DE ALÇA  
17 
 
 
Introduzida no mercado há 45 anos, a furosemida – um potente diurético de alça – alterou a 
história dos pacientes com  insuficiência cardíaca. Desde então, salvou a vida de muitas pessoas em 
edema agudo de pulmão e eliminou a prática das sangrias. Seu uso intravenoso promove uma rápida 
diurese e natriurese. Os diuréticos de alça são, até hoje, os mais usados em quadros edematosos. Seu 
mecanismo de ação consiste na inibição do co-transportador Na+-K+-2Cl- na porção ascendente da 
alça de henle, onde aproximadamente um terço do sódio é reabsorvido. O diurético de alça inibe a 
reabsorção de água e sódio e aumenta a excreção do potássio, magnésio e cloreto. Furosemida, 
bumetanide, torsemide e ácido ethacrynic são os representantes dessa classe de diuréticos(22). 
Diuréticos aparecem como base do tratamento de pacientes com insuficiência cardíaca crônica 
ou em episódios de descompensação. No entanto, apesar de seus benefícios na resolução de quadros 
de congestão com aumento da diurese, estudos apontam que a depleção de eletrólitos e a redução da 
volemia no intravascular provocam a ativação do Sistema renina angiotensina aldosterona e outros 
sistemas neuro-hormonais que podem perpetuar o quadro de congestão(23,24). 
 
1.1.4 RECOMENDAÇÕES PARA O USO DE DIURÉTICOS DE ALÇA. 
 As recomendações da diretrizes terapêuticas atuais são unanimes ao restringir o uso de 
diuréticos para pacientes (25) com sinais e sintomas de congestão, mas reforçam a falta de evidência 
para tal recomendação e a necessidade de sólidas evidências científicas que avaliem a eficácia e 
segurança dos diuréticos de alça (26). 
 A diretriz brasileira de IC crônica, publicada em 2012, recomenda o uso de diuréticos em 
pacientes com sinais e sintomas de congestão com grau de recomendação I e nível de evidência C 
(27). Já o Consenso Europeu de 2016, além de recomendar o uso de diurético de alça para redução 
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de sintomas em pacientes hipervolêmicos (IB), recomenda o uso de diurético de alça para reduzir 
hospitalizações com grau de recomendação IIa e nível de evidência B (26). Não diferente, a diretriz 
da sociedade Americana coloca os diuréticos de alça como tratamento para pacientes com disfunção 
sistólica e retenção de fluídos com o objetivo de melhorar sintomas (IC) (25).  
 Ambas diretrizes, da sociedade europeia e da americana, usam como referência para 
recomendação a metanálise da Cochrane publicada por Faris em 2014, que mostrou redução 
significativa de mortalidade e hospitalização na análise de 14 estudos com 525 pacientes comparando 
o uso de diurético de alça versus placebo, digoxina ou inibidores da enzima conversora de 
angiotensina (IECA) (28). A metanálise de Faris foi retirada do PubMed, em abril de 2016, por 
questões metodológicas e erros de seleção da população dos estudos incluídos (29). Portanto, os 
maiores consensos para manejo de IC fazem uma recomendação usando um estudo com erros 
metodológicos. 
 
1.1.5 ESTUDOS OBSERVACIONAIS COM DIURÉTICOS DE ALÇA 
 Estudos observacionais apontam para um efeito deletério pelo uso prolongado de diuréticos, 
provocando perda de função renal e aumento da mortalidade. Acredita-se que o uso de furosemida 
em doses elevadas resulte em redução do volume intravascular circulante, sinalizando a ativação do 
sistema renina-angiotensina, junto com uma redução compensatória dos peptídeos natriuréticos (30). 
Diuréticos também podem contribuir para progressão da doença por provocarem depleção de 
eletrólitos, distúrbios dos minerais ósseos, hipotensão e fibrose miocárdica. Em subanálise do estudo 
SOLVD, verificou-se que os pacientes euvolêmicos recebendo furosemida apresentavam um 
aumento na atividade da renina plasmática (31).  
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 Em estudo com análise de pontuação de tendências com pacientes ambulatoriais NYHA 
classes I-II, Dini et al. demonstraram que o risco de morte aumenta linearmente com o aumento das 
doses diárias de furosemida estratificadas por quartis. A dose de 50 mg/dia foi identificada como 
valor limite para predizer a maior mortalidade em três anos (32). Do mesmo modo, Damman et al. 
em subanálise do estudo CORONA mostraram que pacientes em uso de furosemida apresentaram 
piora da função renal, independente da dose utilizada, e que o grupo de pacientes com dose > 80 mg 
apresentou maior mortalidade e hospitalização (33).  
 No entanto, especula-se se os diuréticos contribuem para o aumento da mortalidade ou são 
apenas marcadores de gravidade e instabilidade. Mielniczuk et al. mostraram, em coorte de 183 
pacientes ambulatoriais com IC, que pacientes em uso de doses > 80 mg/dia apresentaram mais 
episódios de instabilidade, hospitalizações e maior mortalidade. Porém, quando ajustada para 
estabilidade clínica, a associação da mortalidade com o uso de diurético perde sua significância (34). 
Outra justificativa na tentativa de inocentar a furosemida e sua relação causa-efeito com mortalidade 
é que a associação entre grave disfunção ventricular e dano crônico à função renal já está bem 
estabelecida e conhecida como Síndrome cardiorrenal. Pacientes com disfunção renal crônica 
necessitam de doses maiores de diuréticos para atingir a concentração transglomerular adequada e 
obter a mesma resposta da droga quando comparados aos pacientes com função renal preservada. A 
disfunção renal está associada com o aumento da mortalidade de forma independente, tanto em 
pacientes sintomáticos quanto em pacientes assintomáticos com disfunção do ventrículo esquerdo 
(35).  
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3. JUSTIFICATIVA 
 Pequenos ensaios clínicos demonstraram melhora hemodinâmica com redução da pressão 
sistólica da artéria pulmonar com o uso de sildenafil em pacientes ambulatoriais com insuficiência 
cardíaca e disfunção ventricular. Considerando o mecanismo pelo qual se justifica o efeito do 
sildenafil acredita-se que o benefício da droga está diretamente relacionado com o tempo de uso. Até 
o presente momento, não existem dados robustos que confirmem esta associação. 
 Na presença da necessidade de orientações mais específicas e seguras a respeito da prescrição 
de diuréticos de alça na população de pacientes crônicos com insuficiência cardíaca, torna-se 
importante a realização de estudos que sumarizem os achados de ensaios clínicos randomizados 
anteriores na intenção de responder a esta questão. 
 Considerando-se que o uso de diuréticos de alça está recomendado para a manutenção da 
volemia, questionar a suspensão de diurético em pacientes euvolêmicos é plausível, especialmente, 
num cenário que estudos observacionais associam o uso de diuréticos com aumento de mortalidade. 
 
4. HIPÓTESE 
 O uso de sildenafil em pacientes ambulatoriais com insuficiência cardíaca e com disfunção 
ventricular tem seu benefício relacionado ao tempo de uso da medicação. 
 O uso de diurético de alça em pacientes com insuficiência cardíaca crônica não apresenta 
benefício. 
 A retirada de diurético de alça em pacientes com insuficiência cardíaca crônica com disfunção 
ventricular, em classe funcional NYHA I-II não é inferior à manutenção da droga. 
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5. OBJETIVOS 
 Avaliar o efeito do uso de diurético de alça sobre o risco de ocorrência de congestão pulmonar 
e sistêmica, em estudos de intervenção em humanos (metanálise); 
 Avaliar a segurança e tolerabilidade da retirada de diurético furosemida em pacientes com IC 
classe funcional NYHA I-II e com fração de ejeção < 45% (ensaio clínico randomizado 
protocolo); 
 Avaliar o efeito do uso de sildenafil sobre parâmetros de capacidade funcional, 
hemodinâmicos e incidência de hospitalização, em estudos de intervenção em humanos 
(metanálise). 
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6. ARTIGO 1 – Efeito associado ao tempo de uso de Sildenafil em pacientes com 
Insuficiência Cardíaca: uma revisão sistemática e metanálise de ensaios clínicos 
randomizados 
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Background: Sildenafil is a selective inhibitor of type 5 phosphodiesterase (PDE5) with favorable 
acute hemodynamic effects in patients with heart failure. However, evidence of time-related benefits 
is limited to small size studies. 
Methods and Results: We conducted a systematic review and meta-analysis of randomized 
controlled clinical trials (RCTs) of sildenafil therapy in patients with heart failure. A systematic 
search was realized by two independent reviewers using MEDLINE, EMBASE, the Cochrane Central 
Register of Controlled Trials (1966-2017), and reports from scientific meetings (2005-2016). 
Reviewers determined methodological quality of studies and extracted descriptive and outcome data. 
Studies were classified in 3 groups based on period of treatment: acute: 60 minutes to 24 hours; mid-
term: >24hours to 6 months; and long-term: more than 6 months. Nine RCTs enrolling 316 patients 
with heart failure were included. Compared to placebo, sildenafil therapy resulted in time-dependent 
improvements in peak VO2: there was no change with acute therapy, and significant step-wise 
increase with mid-term (+2.55 ml.kg−1.min−1, 95% CI 0.20 to 4.91, p=0.03), and long-term therapy 
(+3.12 ml.kg−1.min−1. 95% CI 1.90 to 4.34, p<0.001).  Similar results were found for the slope of 
increase in ventilation over carbon dioxide output (VE/VCO2 slope), and LV ejection fraction. On 
the other hand, reduction in systolic pulmonary arterial pressure (PAP) was observed across all time 
points, and it was also more pronounced with mid and long-term follow-up. Finally, pooled analysis 
showed a significant reduction in all-cause hospitalizations with sildenafil treatment (RR 0.29, 95% 
CI 0.11 to 0.78, p=0.01). 
Conclusions: Sildenafil use appears to have time-related benefits on reducing pulmonary 
hypertension and on improving left ventricular and exercise performances in patients with stable heart 
failure. Pooled data also showed a benefit on reducing hospitalizations. Adequately powered RCTs 
are needed to evaluate its role on heart failure survival. 
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Introduction 
Pulmonary hypertension is highly prevalent in patients with heart failure, present in 42% to 
80% of patients with severe left ventricular (LV) systolic dysfunction (1,2). It has also been 
increasingly recognized as a consequence of heart failure with preserved left ventricular ejection 
fraction (LVEF)(3,4). Pulmonary hypertension usually develops as a consequence of impaired LV 
relaxation and distensibility, and has innumerous adverse anatomical and functional effects on the 
pulmonary capillaries, arterial and venous circulation, and right ventricular function (3). The presence 
of pulmonary hypertension is usually associated with worse prognosis in patients with heart failure 
(2,4,5). 
Sildenafil is a selective inhibitor of type 5 phosphodiesterase (PDE5), the main 
phosphodiesterase isoform responsible for the hydrolysis of intracellular cyclic guanosine mono-
phosphate (cGMP) in the pulmonary vasculature, ultimately leading to a selective vasodilatory effect 
(6,7). It has been successfully used to treat erectile dysfunction and has been shown to improve 
exercise capacity and decrease pulmonary vascular resistance in patients with either group 1 or group 
2 pulmonary arterial hypertension (8-11). 
After PDE5 inhibition efficacy was proven in the aforementioned settings, other studies have 
been published evaluating its safety and acute effects in heart failure patients with different etiologies 
and ventricular functions(12,13). Further studies were then performed to assess its long-term effects, 
most of which demonstrated lasting benefit in this subset of patients, even in the absence of significant 
pulmonary hypertension (14-17) However, studies evaluating sildenafil in patients with heart failure 
are limited to small sample sizes and results are therefore mostly restricted to hemodynamic findings 
with no robust data about clinical benefits of this therapy. The aim of the present study was to perform 
a systematic review and meta-analysis of randomized, controlled trials of sildenafil in patients with 
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heart failure. We examined the acute and chronic effects of sildenafil on pulmonary arterial pressure 
(PAP), LVEF, peak oxygen consumption (VO2), the slope of increase in ventilation over carbon 
dioxide output (VE/VCO2 slope), and its chronic effects on hospitalizations in these patients. 
 
Methods 
Search Strategy 
We searched MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled 
Trials, and ClinicalTrials.gov. All searches were not limited to time-period or languages. Searches 
were performed between December 2016 and January 2017. The MEDLINE database was searched 
using MeSH keywords including sildenafil, heart failure, and randomized controlled trials. The 
Cochrane Library and Central Register of Controlled Trials were searched using exploding keywords 
including sildenafil and 5-phosphodiesterase inhibitors. The EMBASE database was searched by 
using exploding keywords sildenafil and heart failure.  We conducted additional searches to identify 
non-published studies reported only at scientific meetings and at ClinicalTrial.gov. We also 
performed electronic searches of the annual scientific sessions of the European Society of Cardiology 
(2005-2016), Heart Failure Society of America (2005-2016), and International Society for Heart and 
Lung Transplantation (2005-2016).  This systematic review and meta-analysis is reported in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement(18).  
Eligibility Criteria 
 Reports of randomized clinical trials (RCT) of sildenafil in patients with heart failure, left 
ventricle systolic dysfunction and elevated pulmonary arterial pressure were included, with no 
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restriction about New York Heart Association (NYHA) functional classification, or comparison agent 
(placebo or other vasodilators). We included trials if they reported at least one of the following as 
outcome data: systolic PAP, either from invasive pulmonary monitoring or echocardiography, peak 
VO2 and/or VE/VCO2 slope from cardiopulmonary exercise test, hospitalization, and mortality. 
Reports of crossover trials were not excluded. Exclusion criteria were as follows: (1) studies of post 
cardiac transplantation, early post-myocardial infarction patients or on left ventricular assistance 
device; (2) children or animal studies; (3) RCTs that evaluated different outcomes from those cited 
above; (4) duplicate publications, where reports with more complete and/or updated data was 
available from the same trial. A PRISMA flow diagram of the study selection process is illustrated in 
FIGURE 1. 
Data extraction and quality assessment 
Eligibility assessment and data extraction were both performed independently by two blinded 
investigators (P.R.R. and E.D.A.). Reviewers were not blinded to authors, institutions, or manuscript 
journals. Abstracts that did not provide enough information regarding the inclusion and exclusion 
criteria were retrieved for full-text evaluation. Reviewers independently evaluated titles, abstracts and 
full-text articles and determined study eligibility. The GRADE approach was utilized to verify the 
quality of reports and the agreement rate between reviewers was = 90% for quality assessment (19) 
(supplement material). Disagreements were solved by consensus and if disagreement persisted, by a 
third reviewer (A.B.). To avoid possible double counting of patients included in more than one report 
by the same working group, patient recruitment periods and baseline characteristics were evaluated. 
The corresponding author was contacted as needed to obtain data not included in the published report. 
Detailed search strategy and grade tables are available at supplementary material. 
Information on participant characteristics, trial design and duration, sildenafil dose, control, 
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and outcomes were extracted using a standardized protocol. Main outcomes included systolic PAP, 
LVEF, peak VO2, VE/VCO2 slope, and number of patients experiencing hospitalization or death. 
We also evaluated other hemodynamic data including systemic vascular resistance and wedge 
pulmonary pressure. Adverse effects as hypotension and bradycardia was evaluated by systemic 
arterial pressure and heart rate.  
Studies were classified in 3 groups based on period of treatment with sildenafil: acute 
response: 60 minutes to 24 hours; mid-term response: >24hours to 6 months; and long-term 
response: more than 6 months.  
Statistical analysis 
Experimental and placebo groups were compared using relative risk (for hospitalization) or 
unstandardized mean differences (systolic PAP, LVEF, peak VO2 and VE/VCO2 slope). Pooled 
estimates across studies and 95% confidence intervals (CI) were determined by meta-analysis using 
the log transformation. The studies were grouped by time of evaluation (acute, mid-term and long-
term). The log transformation with the Mantel_Haenszel method was used for relative risk estimation 
and no transformation with the inverse variance method was used for mean differences. Between 
studies heterogeneity was assessed using the I2 statistics and the p-value from the Q test. I2 above 
50% was considered high heterogeneity and the random effects model with DerSimonian and Laird 
estimation method was then used. Comparison among subgroups was carried out using Bonferroni 
criterion. All analyses were carried out in Stata statistical software version 10.0 (StataCorp LP, 
College Station, Texas). 
 
Results 
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We initially identified 2089 potentially relevant reports. Of these, 1913 reports were excluded 
based on title and abstract. Full-text versions of the remaining 68 reports were then retrieved for 
detailed evaluation. Of these, 59 reports were excluded for reasons listed in Figure 1. Briefly, 12 
presented different outcomes and 12 trials with different population from those studied in this meta-
analysis, 6 review and 5 letters were between reports. The remaining 9 randomized controlled trials 
were included in the meta-analysis. 
All included studies were randomized, double-blinded, placebo-controlled trials. A total of 
316 patients were randomized. Characteristics of the selected studies are summarized in Table 1.  
Three trials had a crossover protocol; all employed a placebo or drug-free wash out period (20-22). 
All trials included only patients with LV dysfunction and mild to moderate secondary pulmonary 
hypertension. Patients had predominantly chronic stable heart failure and were on optimized 
treatment. The proportion of patients on NYHA functional class IV across the studies was small (4% 
to 13%). The mean age of participants ranged between 45 and 72 years. Male subjects comprised 
77% to 100% of the enrollees. 
 On time-dependent analysis, sildenafil therapy resulted in stepwise improvements on peak 
VO2: no significant acute effects (+1.62 ml.kg−1.min−195% CI -1.62 to 4.87), increase at mid-term 
therapy (+2.55 ml.kg−1.min−195% CI 0.20 to 4.9), and further increase at long-term (+3.12 
ml.kg−1.min−195% CI 1.90 to 4.34) (Figure 2A). Likewise, VE/VCO2 slope improved at mid and long-
term follow-up (mid-term, -6.28, 95% CI -9.07 to -3.49; long-term -7.78, 95% CI -11.06 to -4.51), 
with no evidence of acute effects (Figure 2B).  
As depicted in Figure 3, analyses of functional and hemodynamic parameters showed a 
stepwise time-dependent improvement on LVEF (acute, + 1.04%, 95% CI -0.48 to 2.55; mid-term + 
5.35%, 95% CI 3.40 to 7.30; long-term + 6.0%, 95% CI 3.25 to 8,75) (Figure 3A). On the other hand, 
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efficacy of sildenafil to reduce systolic PAP was observed early after intervention (reduction of -8.56 
mmHg, 95% CI -10.33 to -6.78 in the acute response group compared to -12.05 mmHg, 95% CI-
14.00 to -10.10 at mid-term and -13.30 mmHg, 95% CI -16.47 to -10.13 in the long-term group) 
(Figure 3B). No difference was found for systemic vascular resistance (Figure 3C). Wedge pulmonary 
pressure values were not changed at acute and mid-term periods, with a subtle reduction at long-term, 
which was analyzed in only one study (Figure 3D).  
All-cause hospitalizations were reported by 3 of the 9 trials for patients with 1, 6 and 12 
months of follow-up. In one study, no events were observed at sildenafil group. All-cause 
hospitalizations were significantly reduced in sildenafil treated patients (RR 0.28, 95% C.I 0.09 to 
0.85), as shown in Figure 4. 
Heart rate and systolic blood pressure (SBP) were evaluated as changes in these variables 
could represent adverse effects of sildenafil. No change was observed for heart rate regardless of the 
time. A small reduction on SBP was observed only in the acute response, and this reduction was not 
observed in mid- and long-term responses (Figure 5).   
 
Discussion 
The present meta-analysis of sildenafil in patients with heart failure has three main findings: 
1) sildenafil therapy reduced pulmonary hypertension and improved left ventricular and exercise 
performances, 2) the detected improvements were not only maintained with long-term use, but also 
increased in magnitude, as for systolic PAP, ejection fraction, peak VO2, and VE/VCO2 slope; and 
3) pooled analysis showed a significant effect on reducing hospitalizations in sildenafil-treated 
patients.  
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Sildenafil, a potent inhibitor of PDE5, produces significant vasodilation mediated by nitric 
oxide (NO) release and cGMP accumulation. Sildenafil has been shown to produce pulmonary and 
systemic vasodilatation, decreased LV filling pressure, and increased cardiac index without causing 
systemic hypotension (26,27). These effects contrast those of most currently used vasodilators, whose 
use is limited by systemic hypotension and depression of myocardial contractility (28,29). Our 
secondary outcomes showed no variance of heart rate ate systolic arterial pressure during sildenafil 
use, suggesting the safety of drug. In addition, the mechanisms for the benefits of sildenafil seem not 
to be restrict to systolic PAP reduction or to its action in the arterial bed; direct endothelial and 
myocardium protective effects have been described and are believed to be important, especially in 
the heart failure scenario (30,31)  
Pulmonary hypertension has been extensively studied in the context of heart failure, mostly 
because of its strong association with mortality in these patients (32,33). The present analysis shows 
an important reduction of systolic PAP with sildenafil, with a time related response. At this meta-
analysis we could only observe the effect of sildenafil on patients presented elevated pulmonary 
arterial pressure. Hryniewicz et al. (25) was the only study without elevated pulmonary hypertension 
as inclusion criteria, but it was not evaluated for primary outcomes. To explain how sildenafil could 
impact on remodeling we need to understand that a pathogenesis of group2 PH is a multistep and 
multifactorial process developing through the progressive mechanical lung capillary injury, vascular 
functional impairment with structural remodeling, and subsequent worsening in right ventricular 
function. Experimental studies and anatomopathological reports have been associated the interstitial 
and alveolar edema with proliferation of myofibroblasts with fibrosis, extracellular matrix deposition 
and increased expression of a series of pro-inflammatory cytokines (34). Once sildenafil promotes 
pulmonary vasodilatation and increases nitric oxide availability, this cascade is interrupted. 
Nonetheless, the question if the benefit of sildenafil is restricted to patients with elevated pulmonary 
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hypertension still without answer. 
 
  Two measures of cardiorespiratory performance, peak VO2 and VE/VCO2 slope, were both 
significantly improved after sildenafil treatment. The peak VO2 improvement, of 3.48 ml.kg−1.min−1, 
represents an improvement which is similar or greater than the expected effect size from conventional 
aerobic or resistance training (34), or from modalities such as cardiac resynchronization therapy (36) 
. VE/VCO2 slope was also significantly reduced in the treatment group. In fact, ventilatory efficiency, 
as assessed by the VE/VCO2 slope, has been shown to be a powerful prognostic marker in the heart 
failure population, superior to peak VO2 in some studies (37,38). Most studies using sildenafil on 
heart failure adopted ventilatory parameters as primary outcomes. 
Another interesting observation from the present meta-analysis is related to the greater 
improvement in systolic PAP and VE/VCO2 slope with long-term treatment. This time-dependent 
continued improvement (i.e., the longer the treatment, the greater the improvement) could suggest 
that the observed findings were not purely related to hemodynamic effects but rather involved arterial 
and/or myocardial remodeling effects which might take place with long-term use. In fact, decreased 
LV and septal wall thickness and LV mass have been shown with chronic sildenafil treatment, 
supportive of direct remodeling and prolusitropic effect on cardiac function(39) and experimental 
studies have been established reduction on inflammatory cytokines and promoting angiogenesis.  
However, one should take this as a hypothesis-generating observation rather than a conclusion from 
the present study. Further studies are needed to better address this issue.  
Accumulated data of individual trials cannot confirm benefits of sildenafil in reducing either 
mortality or hospitalization when compared to placebo in patients with heart failure reduced ejection 
fraction (HFrEF). The present meta-analysis demonstrates that sildenafil significantly reduced the 
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risk of all-cause hospitalizations in these patients and the time-dependent effect on hemodynamic 
parameters (40,41). Our analysis, however, should be seen in a conservative way given the reduced 
number of trials and the small population enrolled by these trials. To the best of our knowledge, this 
represents the largest number of analyzed patients. 
It is important to consider some published trials with sildenafil on heart failure that were not 
described on this meta-analysis because they didn’t fill up inclusion criteria, although their results 
corroborate with our findings. Bocchi et al. showed significant improvement at exercise capacity after 
a 50 mg of sildenafil on 6-minute-walking and cardiopulmonary exercise test on an acute evaluation 
(42). Curoto-Grasiosi et al. in a 70 patients clinical trial also demonstrated improvement of exercise 
capacity after 2 hours of 50 mg of sildenafil on 6-minute-walking-test (43). RELAX was the only 
multicenter double blind trial, with robust sample of heart failure patients with preserved left ventricle 
function followed by 24 weeks and was not able to reach any significant outcome, including exercise 
capacity (44). A protocol of a multicenter trial with HFrEF patients has been published on 2012 but 
this study has suspended participant recruitment recently (45). 
The present study has some limitations. The selected trials were small size studies, majority 
of them comes from a single institution which increase a risk of bias. The GRADE approach was 
moderate for 5 studies and high for 4 studies. and in general their quality was low, with increased risk 
of bias in some studies. However, intervention and placebo groups were similar for most studies. 
Some desired variables, as NYHA functional class, 6-minute-walking test and NT-proBNP was not 
included in our meta-analysis because missing data on trials. Also, heterogeneity was found for VO2 
peak and VE/VCO2 slope analyses but only at acute sub analysis; however, these might be explained 
by the observed relation between effect sizes and duration of therapy. Finally, small number of 
outcomes limits a more definite conclusion about the effects of sildenafil on prognosis. 
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Conclusions 
Sildenafil improves exercise performance, PAP, and LV function in patients with heart 
failure, and the effect on peak VO2, VE/VCO2 slope and systolic PAP were not only sustained but 
greater with long-term use. Also, there is evidence for a significant effect on reducing hospitalizations 
in this group of patients. Properly powered RCTs should further address its effects on long-term 
prognosis in heart failure. 
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Figure Legends 
Figure 1. Flowchart of the search strategy of studies. 
 
Figure 2. Mean difference in functional parameters at acute, mid-term and long-term  in the trials 
considering sildenafil compared to placebo therapy on EFrHF patients. A: peak of oxygen 
consumption VO2 and B: VE/VO2 slope. 
 
Figure 3. Mean difference in functional and hemodynamics parameters at acute, mid and long term  
in the trials considering sildenafil compared to placebo therapy on EFrHF patients. A: ejection 
fraction (%); B: pulmonary artery systolic pressure (mmHg); C: systemic vascular resistance 
(dyn·s/cm-5) and D: wedge pulmonary pressure (mmHg). 
 
Figure 4. Relative risk of hospitalizion at mid and long term  in the studies considering sildenafil 
compared to placebo therapy on EFrHF patients. 
 
Figure 5.  Control of adverse effects represented by mean difference in heart rate in beats per minute 
(A) and systolic blood pressure in mmHg (B) at acute, mid and long term  in the trials considering 
sildenafil compared to placebo therapy on EFrHF patients.  
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Table 1- Baseline characteristics of trials included in the meta-analysis. 
Source Design Dose 
mg 
Follow up Group N Age mean 
(SD), y 
Functional 
Class, NYHA 
Ejection 
Fraction,% 
 
Pulmonary 
Systolic Arterial 
Pressure, mmHg* 
Etiology 
Ischemic,% 
Drugs,% 
ACE or ARB/BB/DIU† 
 
Guazzi 
2004(21) 
Crossover 50  60 minutes Sildenafil/Placebo 16 55.1±8.2 II-III 30.2±3.2 34.7±3.2* 68 87/68/100 
Guazzi 
2004(22) 
Crossover 50  60 minutes Sildenafil/Placebo 10 57.9±4.5 II-III ≤40 32.9±2.7* 60 80/60/100 
Hryniewicz 
2005(25) 
Parallel 50 60 minutes 
Sildenafil 16 57±3 II-III 27±3 
-- 
25 100/87/75 
Placebo 16 54±2 II-III 23±2 50 100/100/81 
Lewis 
2007(24) 
Parallel 225¶  90 days Sildenafil 17 54±4 II-IV 19±2 30±2.0§ 47 77/100/100 
Guazzi 
2008(20) 
Crossover 
 
150 
60 minutes 
 
Sildenafil/Placebo 16 56.6±4.3 II-III 31.8±2.2 35.3±2.2* 62 93/75/81 
Parallel 150 30 days Sildenafil 11 45±12 I-III 27±5 56±13* 36 100/91/100 
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Behling 
2008(23) 
Placebo 8 53±11 I-III 30±7 62±23* 25 100/88/100 
Guazzi 
2007(14) 
Parallel 150  180 days 
Sildenafil 23 62±3 II-III 30.6±3.0 33.7±3.1* 47 82/60/69 
Placebo 23 63±4 II-III 31.9±3.3 31.9±2.7* 43 78/69/65 
Guazzi 
2012(15) 
Parallel 150  365 days 
Sildenafil 16 66±8 III-IV 29.0±8.0 34.8±4.0§ 31 81/81/- 
Placebo 16 68±6 III-IV 28.0±7.0 34.0±3.0§ 43 69/75/- 
Guazzi 
2011(17) 
Parallel 150  365 days 
Sildenafil 23 60±4 II-III 29.5±3.0 37.1±4.3* 47 83/78/- 
Placebo 22 61±4 II-III 30.2±4.0 37.7±3.9* 54 90/90/- 
* Pulmonary arterial pressure denotes pulmonar systolic arterial pressure. 
† ACE –  angiotensin-converting-enzyme inhibitor, ARB - angiotensin receptor blockers, BB – beta-bloquers, DIU – diuretics. 
‡ Age expressed by mean and maximum and minimum age. 
§ Pulmonary arterial pressure expressed by mean pulmonar arterial pressure. 
¶  The initial dose of study medication was 75 mg daily and was up-titrated every 2 weeks to 250 mg daily as tolerated. N/A – not available data 
47 
 
Figure 1. Flowchart of the search strategy of studies. 
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Figure 2. 
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Figure 3. 
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Figure 5. 
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Supplements 
 
Structured search. 
"sildenafil" [Supplementary Concept] OR "desmethyl sildenafil" 
OR"desmethylsildenafil" OR "homosildenafil" OR "Viagra" OR "Pfizer brand 1 of 
sildenafil citrate" OR "Abbott brand of sildenafil citrate" OR "Revatio" OR "Pfizer brand 
2 of sildenafil citrate" OR "sildenafil citrate" OR "UK 92480-10" OR "UK-92,480-10" 
OR "acetildenafil" OR "hydroxyhomosildenafil" AND "Heart Failure"[Mesh] OR 
"Cardiac Failure" OR "Myocardial Failure" OR "Heart Failure, Left-Sided" OR "Heart 
Failure, Left Sided" OR "Left-Sided Heart Failure" OR "Left Sided Heart Failure" OR 
"Heart Failure, Right-Sided" OR "Heart Failure, Right Sided" OR "Right-Sided Heart 
Failure" OR "Right Sided Heart Failure" OR "Congestive Heart Failure" OR "Heart 
Failure, Congestive" OR "Heart Decompensation" OR "Decompensation, Heart" AND 
(randomized controlled Trial[pt] OR controlled clinical Trial[pt] OR randomized 
controlled trials[mh] OR random allocation[mh] OR Double-blind method[mh] OR 
single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR (“clinical 
trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND 
(mask*[tw] OR blind*[tw]) OR (“latin square”[tw]) OR placebos[mh] OR placebo*[tw] 
OR random*[tw] OR research design[mh:noexp] OR follow-up studies[mh] OR 
prospective studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] 
OR volunteer*[tw]) NOT (animal[mh] NOT human[mh]) 
 
 
 
Table 1: Grade summary of evidence for outcomes hospitalization, left ventricule 
ejection fraction and pulmonary systolic arterial pressure. 
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Sildenafil compared to Placebo in heart failure patients 
Patient or population: heart failure patients  
Setting: Ambulatorial patients  
Intervention: Sildenafil  
Comparison: Placebo  
Outcomes Anticipated absolute 
effects* (95% CI)  
Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
Placebo 
Risk with 
Sildenafil 
Hospitalization 
(Hospitalization) 
follow up: range 
3 months to 12 
months  
225 per 
1.000  
61 per 
1.000 
(16 to 216)  
RR 0.27 
(0.07 to 
0.96)  
80 
(2 RCTs)  
⨁⨁⨁⨁ 
HIGH a 
NNT = 6  
Left Ventricule 
Ejection 
Fraction (LVEF) 
assessed with: % 
follow up: mean 
6 months  
The mean 
left 
Ventricule 
Ejection 
Fraction was 
30.5 %  
The mean 
left 
Ventricule 
Ejection 
Fraction in 
the 
intervention 
group was 
5,35 % more 
(3,4 more to 
7,3 more)  
-  86 
(2 RCTs)  
⨁⨁⨁⨁ 
HIGH a 
 
Pulmonary 
Systolic Arterial 
Pressure (PSAP) 
assessed with: 
mmHg 
follow up: mean 
6 months  
The mean 
pulmonary 
Systolic 
Arterial 
Pressure was 
37.3 mmHg  
The mean 
pulmonary 
Systolic 
Arterial 
Pressure in 
the 
intervention 
group was 
12,05 mmHg 
fewer (14 
fewer to 10,1 
fewer)  
-  105 
(3 RCTs)  
⨁⨁⨁⨁ 
HIGH  
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and 
the relative effect of the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio; MD: Mean difference  
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from 
the estimate of effect  
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Figure 1. Mean difference in the outcome of peak of oxygen consumption VO2 at acute, 
mid and long term  in the trials considering sildenafil compared to placebo therapy on 
EFrHF patients. 
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Figure 2. Mean difference in the outcome of VE/VO2 slope at acute, mid and long term  
in the trials considering sildenafil compared to placebo therapy on EFrHF patients. 
 
 
56 
 
 
Figure 3. Mean difference in ejection fraction (%) at acute, mid and long term  in the trials 
considering sildenafil compared to placebo therapy on EFrHF patients. 
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Figure 4. Mean difference in pulmonary artery systolic pressure (mmHg) at acute, mid 
and long term  in the studies considering sildenafil compared to placebo therapy on 
EFrHF patients. 
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Figure 5. Mean difference in systemic vascular resistance (dyn·s/cm-5) at acute, mid and 
long term  in the studies considering sildenafil compared to placebo therapy on EFrHF 
patients. 
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Figure 6. Mean difference in wedge pulmonary pressure (mmHg) at acute, mid and long 
term  in the studies considering sildenafil compared to placebo therapy on EFrHF patients. 
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Figure 7. Mean difference in heart rate (beats/minute) at acute, mid and long term  in the 
studies considering sildenafil compared to placebo therapy on EFrHF patients. 
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Figure 8. Mean difference in systolic arterial pressure (mmHg) at acute, mid and long 
term  in the studies considering sildenafil compared to placebo therapy on EFrHF patients. 
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7. ARTIGO 2 – Diurético de alça na Insuficiência Cardíaca crônica: uma 
revisão sistemática e metanálise de ensaios clínicos randomizados 
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Abstract 
Background: The use of diuretics is an important tool for the treatment of both chronic and 
acute decompensated heart failure. Despite the undeniable beneficial effects improving 
peripheral and central congestion, the chronic maintenance of diuretics in HF patients may be 
unnecessary and may even compete with other, life-saving, therapies. We therefore sought to 
investigate the evidence for or against diuretic use in chronic HF patients. 
Methods and Results: We conducted a systematic review and meta-analysis of randomized 
controlled trials of henle loop diuretic compared to usual care, placebo or dose reduction. A 
systematic search was realized by two independent reviewers using MEDLINE, EMBASE, the 
Cochrane Central Register of Controlled Trials (1966-2017). Keywords were “randomized 
controlled trial”, “heart failure”and “diuretics”. Data extraction was standardized according 
to the inclusion and exclusion criteria and GRADE Pro software was used to qualify the 
evidence. Eight RCTs enrolling 246 patients with heart failure were included. Follow-up ranged 
from 7 days to 12 months. Compared to control group, patients receiving henle loop diuretic 
had no difference in weight, systolic blood pressure or serum levels of potassium. Analysis of 
the outcome worsening congestion, showed benefits of diuretic use when compared to 
no/reduction of diuretic (RR 0.20, 95% CI 0.06 to 0.65, p<0.01), without difference when 
compared to thiazide diuretic (RR0.80, 95% CI 0.19 to 3.37, p=0.95).  
Conclusions:  Despite common use, the evidence supporting either to maintain or withdraw 
loop diuretics in patients with chronic HF without congestion is poor. Adequately powered 
trials are needed to evaluate the efficacy of henle loop diuretics on chronic heart failure as well 
as the safety of diuretics withdraw in this scenario. 
Introduction 
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Chronic heart failure (HF) patients require lifelong treatment with multiple medications. 
Drug therapy for HF has greatly improved in the last 30 years, impacting in HF-related 
morbidity and mortality. Since these unquestionable advances were reached, the efficacy of old 
drugs as furosemide and digoxin have been questioned (1). The idea that diuretics are the 
mainstay of treatment in chronic HF should be reviewed. Considering that benefits are related 
to the control of hypervolemia resulting in reducing ventricular filling pressures and pulmonary 
venous congestion, there is no biological plausibility to use furosemide on euvolemic patients 
with stable HF. Following this precept, current clinical guidelines suggest the use of diuretics 
in HF patients with clinical signs and symptoms of congestion, but reinforce the lack of solid 
clinical scientific evidence for this recommendation, and the potential risks that might be 
involved (2,3).  
The discussion about the role of diuretics on worsening renal failure, electrolyte disturbs 
and even in the potential increase of mortality is ongoing. Long-term use of loop agents has 
been associated with mortality in a dose-dependent manner in observational studies, is believed 
that overuse of diuretics promotes neurohormonal activation (4,5). However, higher doses 
might represent an indirect measure of severity of disease that justifies higher mortality, 
Mielnickzuk et al. shows that high-dose diuretics may be more of a marker than a cause of 
instability, high-dose of diuretics were a strong univariate predictor of subsequent HF events, 
however, after adjustment for clinical stability diuretic dose no longer remained significant (6). 
 
 
Based on these uncertainties about diuretic use in HF, this meta-analysis was designed 
to evaluate the randomized controlled trials that have tested the effects of henle loop diuretics 
use in stable, chronic HF outpatients. 
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Methods 
Study design 
The present systematic review and meta-analysis included studies 
evaluating chronic HF patients using henle loop diuretics. 
 
Search strategy 
 Randomized controlled trials of several classes of diuretics compared to usual care, 
placebo, withdrawn/dose reduction were eligible to be included in this analysis if they were 
published in full in a peer-reviewed journal. These studies were found through a literature 
search in the PubMed and EMBASE database from 1950 to February 2017. Keywords were 
“randomized controlled trial”, “heart failure” and “diuretics”. A search in Cochrane Library 
was also performed. For use in the sensitivity analysis, additional meta-analyses that met the 
previously mentioned criteria were analyzed. Search was realized between November 2016 and 
February 2017. Detailed search strategy is available at the supplementary material. 
 
Eligibility criteria 
 Randomized controlled trials (RCT) with henle loop diuretic with no restrictions for a 
control group were included in the meta-analyses. Studies published in languages other than 
English were excluded. Studies had to examine the effects henle loop diuretic on outpatients 
with HF with no limits regarding left ventricle ejection fraction (LVEF) or New York Heart 
Association (NYHA) functional class. Studies on combination therapy were excluded. 
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Data extraction and quality assessment 
 Two reviewers (L.M and S.A) independently reviewed the results of each search 
according to the inclusion and exclusion criteria, with a standardized data extraction tool and 
also applied standard scales to judge study quality and risk of bias. A third reviewer (M.B) 
adjudicated in cases of doubt. 
 The primary outcome collected from the studies was number of patients that presented 
worsening of clinical status because of progression of congestion. Because HF hospitalization 
can be defined as worsening of congestion in most cases, and in order to ensure sufficient data 
for a meaningful analysis, HF hospitalization was included in the worsening of congestion 
outcome. This systematic review and meta-analysis is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (7). A 
PRISMA flow diagram of the study selection process is illustrated in FIGURE 1. Tables with 
grade assessment of evidence quality are available as supplementary material. 
 
Statistical analysis 
Meta-analyses of progression of congestion with the need to initiate furosemide were 
performed using a fixed effects model, risk ratios (RRs). Experimental and control groups were 
compared using unstandardized mean differences (creatinine and potassium serum levels, 
systolic blood pressure and weight). Pooled estimates across studies and 95% confidence 
intervals (CI) were determined by meta-analysis using the log transformation. The studies were 
grouped by control category (thiazide o no/reduction diuretic dose). The log transformation 
with the Mantel_Haenszel method was used for relative risk estimation and no transformation 
with the inverse variance method was used for mean differences. Between studies heterogeneity 
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was assessed using the I2 statistics and the p-value from the Q test. I2 above 50% was considered 
high heterogeneity and the random effects model with DerSimonian and Laird estimation 
method was then used. All analyses were carried out in Stata statistical software version 10.0 
(StataCorp LP, College Station, Texas). 
 
Results 
We initially identified 5212 potentially relevant reports. Of these, 632 reports were 
duplicates or not in English. While 246 studies were selected by abstracts, 73 full-text versions 
of the remaining reports were then retrieved for detailed evaluation. Of these, 65 studies were 
excluded for reasons listed in Figure 1. The remaining 8 RCT were included in the meta-
analysis with moderate evidence quality assessment. 
 Most included studies were randomized, double-blind controlled trials, except for one 
open label design and one single blinded study. One trial had a crossover protocol; and one trial 
had an open label design (15,14). Four trials included patients with LV dysfunction, 2 trials 
included patients with preserved LVEF and 2 trials did not report on ventricular function. 
Patients had chronic HF and were on different drugs; only 3 studies included patients on 
optimized HF treatment. All patients were on NYHA functional class I to III across the studies. 
The studies varied in size from 24 to 97 patients, totalizing 342 patients. Patients were on 
average 64.1 years old, and male patients were overrepresented in all studies, making up 81% 
of the sample. Follow-up ranged from 7 days to 12 months. Table 1 shows baseline 
characteristics of the study populations. 
Compared to control group, henle loop diuretic therapy resulted in significant better 
control of volemia, resulting in less events of worsening of congestion (RR 0.20, 95% CI 0.06 
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to 0.65, p<0.01) (Figure 2). On the other hand, efficacy of henle loop diuretic versus thiazide 
diuretic at the same outcome was similar (RR0.80, 95% CI 0.19 to 3.37, p=0.95) (Figure 3). 
As depicted in Figure 4, analyses of serum creatinine levels did not reach statistical 
difference (0.00, 95% CI -0.07 to 0.07, p=0.97), as well as serum potassium levels (-0.31, 95% 
CI -0.71 to 0.10, p=0.13). 
Evaluation of body weight was presented in only two trials and there was no difference 
between groups when followed by 6 to 12 weeks (-0.22, 95% CI -7.39 to 6.96, p=0.76). Systolic 
blood pressure shows a tendency to reduction with henle loop diuretic, but the difference was 
not significant (-2.91, 95% CI -13.66 to 7.84, p=0.59). 
 
Discussion 
The present meta-analysis of henle loop diuretics in patients with HF highlights the lack 
of evidence either to maintain or withdraw this therapy in this population. Pooled analysis 
totaling only xx events resulted in a significant effect of maintaining loop diuretics on reducing 
worsening of congestion as compared to withdraw, but not when compared to the use of thiazide 
diuretic. No effects were observed on renal function, potassium serum levels, weight and 
systolic blood pressure. Importantly, in most studies patients were not on optimized HF 
therapies and therefore these results must be seen with caution. 
 Besides a number of titles related with the theme, just a small proportion were 
randomized trials, most of them from 80’ decade when the knowledge and the treatment about 
HF were far from the nowadays clinical practice. Recently, the only meta-analysis published 
about this subject was withdrawn from Cochrane database, the author claims misinformation 
about studies population (16,17). Both American and European guidelines quote the Cochrane 
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meta-analysis (2,4). In face of this scenario we believe that our biggest contribution is to present 
a strictly delineated systematic review, that reveals no data about mortality, and scarce data on 
clinical outcomes, on clinical trials with henle loop diuretic. 
 Accumulated data of individual trials shows benefits of henle loop agents in reducing 
congestion when compared to placebo, diuretic withdrawn or 1/3 reduction dose in outpatients 
with HF. Otherwise the significant benefit on controlling congestion was demonstrated only in 
two trials. In the study by Haerer et al. (9) patients were treated only with nitrate as background 
therapy and in Patterson et al. (10) therapy included digoxin and angiotensin-converter-enzyme 
inhibitors. Both studies included patients with left ventricular dysfunction and mostly on 
functional class NYHA III. Moreover, at Haerer et al. patients needed to present an elevated 
pulmonary wedge pressure as inclusion criteria. In fact, the better performance of henle loop 
agents on these studies could be expected as patients presented hypervolemia and were not on 
optimized HF therapy.  
 Another interesting observation from the present meta-analysis is related to the 
comparison of furosemide and thiazide diuretics on worsening of congestion. The similar 
response with both diuretics suggests that thiazide diuretics may be an option to treat chronic 
HF beyond its use associates with furosemide on diuretic resistant patients at decompensation 
(18). 
 Contradicting previous observational studies (19,20), the meta-analysis did not show 
worsening of renal function or hypokalemia with diuretic use. We could speculate that trials 
that tested creatinine serum levels compared 2 diuretics already associated with creatinine 
elevation. Potassium pooled analysis were not statistically significant, nevertheless, Vermeleun 
et al. (12) showed an important reduction of serum potassium levels in the furosemide group 
comparing to hydrochlorothiazide, but background therapy did not include ACE-inhibitors or 
mineralocorticoids. With a bigger sample Pehrsson et al. (13), that also compared furosemide 
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to thiazide diuretic on poorly treated patients, did not find difference on potassium levels. Ogino 
et al. (15) demonstrated a reduction of potassium comparing furosemide with spironolactone, a 
known potassium –sparing-diuretic.  
 No difference on body weight in patients treated with furosemide or thiazide diuretic 
could suggest similar performance on volemia control with both diuretics. Systolic blood 
pressure responded equally to furosemide, hydrochlorothiazide or spironolactone. 
 
Limitations 
 The literature search showed most of articles from 80 and 90 decades and the standard 
therapy of HF has changed over the last decades. Many of those studies brought furosemide as 
a control group for phase II-III clinical trials of drugs that were not approved. As well, several 
studies could not be included because of methodological issues at old studies, and eleven 
antique studies were not available after many attempts to reach them. Finally, we initially 
intended to evaluate only trials with HF with reduced EF, but changed to include any EF range 
as many studies did not report LVEF and that would make the meta-analysis not performable,  
 
Conclusions 
 The evidence either to maintain or withdraw therapy with loop diuretics in patients with 
chronic HF is scarce. Although pooled data suggest benefit of loop diuretics on worsening 
congestion, in several studies patients were not on optimized HF therapy. Well design trials 
evaluating the use of diuretics on patients with optimized background HF therapy must be 
performed in order to elucidate their role in this context. 
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Figure Legends 
 
Figure 1. Flowchart of the search strategy of studies. 
 
Figure 2. Relative risk of worsening of congestion in the studies considering henle loop diuretic 
compared to no/reduction of diuretic on HF patients. 
 
Figure 3. Relative risk of worsening of congestion in the studies considering furosemide diuretic 
compared to thiazide diuretic on HF patients. 
 
Figure 4. Mean difference in serum level of creatinine, serum level of potassium, systolic blood 
pressure and weight in the trials considering henle loop diuretic compared to active control 
therapy on HF patients. 
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Table 1- Baseline characteristics of trials included in the meta-analysis. 
 
  
Study, year Drug Control  N  
drug/control 
Age 
(mean) 
NYHA 
functional 
class 
EF 
(mean)% 
Background 
Therapy 
Study 
Design 
Follow-up  
Kraaij 2000 (8) Furosemide Placebo 
Withdraw 
21/11 75 I-III 60 BB/ACE/DIG/NIT ECR, 
doble-
blind 
3 months 
Haerer 1990 
(9) 
Piretanide Placebo 46/14 52.4 II-III HFrEF NIT ECR, 
single-
blind 
3 weeks 
Patterson 1994 
(10) 
Torsemide Placebo 10/14 60.2 II-III 27.2 ACE/DIG ECR, 
doble-
blind 
7 days 
Kapelios 2014 
(11) 
Furosemide Placebo 
Decrease 1/3 
20/20 62.2 1.9 27.3 BB/ACE/ARAII/DIG ECR, 
doble-
blind 
12 months 
Vermeulen 
1982 (12) 
Furosemide Hydroclorothiazide 14/12 60.5 I-III - DIG/BB/NIT/CCB ECR, 
doble-
blind 
6 weeks 
Pehrsson 1985 
(13) 
Furosemide Bendroflumethiazide 24/23 65 II-III - DIG ECR, 
doble-
blind 
12 weeks 
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Miyata 2012 
(14) 
Furosemide Azosemida 49/48 75 I-III 58.9 BB/ACE 
NIT/DIG/MRA 
ECR, 
open-
label 
12 weeks 
Ogino 2014 
(15) 
Furosemide Espironolactona 16 63 I-III 34.4 ACE/ARAII/BB ECR, 
doble 
blind, 
crossover 
16 weeks 
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Figure 1. 
5212 Potentially relevant publications screened 
73 full-text articles retrieved for detailed review  
8 Randomized controlled trials  
PubMed 4569 
records 
EMBASE 
639 records 
Cochrane Library and 
additional manual search 
4 records 
343 selected by title 
632 records excluded for 
duplicated ou not published in 
english 
246 selected by abstracts 
66 Excluded 
 2 not English 
11 not accessible 
4 incomplete information 
18 inadequate design 
21 different intervention or 
comparator 
6 different population 
4 different outcomes and 
measures 
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Supplement Material 
 
Structured search. 
 
((("Heart Failure"[Mesh:NoExp]OR "Cardiac Failure" OR "Heart Decompensation" OR 
"Decompensation, Heart" OR "Heart Failure, Right-Sided" OR "Heart Failure, Right 
Sided" OR "Right-Sided Heart Failure" OR "Right Sided Heart Failure" OR "Myocardial 
Failure" OR "Congestive Heart Failure" OR "Heart Failure, Congestive" OR "Heart 
Failure, Left-Sided" OR "Heart Failure, Left Sided" OR "Left-Sided Heart Failure" OR 
"Left Sided Heart Failure")) AND ("Diuretics"[Mesh] OR "Diuretic Effect" OR "Effect, 
Diuretic" OR "Diuretic Effects" OR "Effects, Diuretic")) AND ((randomized controlled 
trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random 
allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR clinical 
trial[pt] OR clinical trials[mh] OR ("clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] 
OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR ("latin square"[tw]) 
OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR 
follow-up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR 
control*[tw] OR prospectiv*[tw] OR volunteer*[tw]) NOT (animal[mh] NOT 
human[mh])) 
 
 
Figure 1: Funnel plot for the studies that evaluates the outcome worse of congestion 
considering henle loop diuretic compared to no/reduction dose of diuretic. 
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Quality assessment  
№ of participants 
(studies) 
Follow-up 
Risk of bias Inconsistency Indirectness Imprecision Publication bias 
Overall quality of 
evidence 
Creatinine serum level mg/dL (follow up: range 12 weeks to 16 weeks; assessed with: mg/dL) 
145 
(3 RCTs)  
not serious  not serious  serious a not serious  all plausible residual 
confounding would 
suggest spurious effect, 
while no effect was 
observed  
⨁⨁⨁⨁ 
HIGH  
Potassium serum level mEq/dL (follow up: range 6 weeks to 16 weeks; assessed with: mEq/dL) 
238 
(5 RCTs)  
not serious  not serious  serious b not serious  all plausible residual 
confounding would 
reduce the demonstrated 
effect  
⨁⨁⨁⨁ 
HIGH  
Systolic blood pressure mmHg (follow up: range 6 weeks to 12 weeks; assessed with: mmHg) 
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Table 1: Grade summary of evidence for outcomes creatinine, potassium, systolic blood pressure and weight. 
 
CI: Confidence interval 
a. Control drug are not from the same class, Ogino 2014 - espironolactone, Nordrehaug 1992 - benazepril and at Miyata 2012 - azosemida. As the 
diuretic group were treated with furosemide at Ogino 2014 e Miyata 2012 and with hydroclorotiazide at Nordrehaug 1992.  
b. No explanation was provided  
c. Control drug are not from the same class, Ogino 2014 - espironolactone, Nordrehaug 1992 - benazepril, Vermeulen 1982-hydroclorothiazide 
and at Miyata 2012 - azosemida. As the diuretic group were treated with furosemide, except for Nordrehaug 1992 treated with hydroclorotiazide.  
 
 
170 
(3 RCTs)  
not serious  not serious  serious c not serious  all plausible residual 
confounding would 
reduce the demonstrated 
effect  
⨁⨁⨁⨁ 
HIGH  
Body weight kg (follow up: range 6 weeks to 12 weeks; assessed with: kg) 
73 
(2 RCTs)  
not serious  not serious  not serious  not serious  all plausible residual 
confounding would 
reduce the demonstrated 
effect  
⨁⨁⨁⨁ 
HIGH  
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Table 1: Grade summary of evidence for outcomes worse of congestion. 
 
a. Small number of patients 
Henle loop diuretic compared to no/reduction dose of diuretic for chronic heart failure 
Bibliography:  
Quality assessment  Summary of findings  
№ of 
participants 
(studies) 
Follow-up 
Risk 
of bias 
Inconsistency Indirectness Imprecision Publication 
bias 
Overall 
quality of 
evidence 
Study event rates (%) Relative 
effect 
(95% CI) 
Anticipated absolute 
effects 
With 
no/reduction 
dose of 
diuretic 
With 
Henle 
loop 
diuretic 
Risk with 
no/reduction 
dose of 
diuretic 
Risk 
difference 
with Henle 
loop diuretic 
Progression of congestion with need to reintroduce henle loop diuretic (follow up: range 3 months to 12 months; assessed with: number of patients) 
156 
(4 RCTs)  
not 
serious  
not serious  not serious  very serious 
a 
all plausible 
residual 
confounding 
would 
reduce the 
demonstrated 
effect  
⨁⨁⨁◯ 
MODERATE  
16/59 
(27.1%)  
4/97 
(4.1%)  
not estimable  271 per 
1.000  
271 fewer 
per 1.000 
(271 fewer to 
271 fewer)  
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8. ARTIGO 3 – Racional e delineamento de um ensaio clínico randomizado, duplo-
cego, estudo multicêntrico para avaliar a segurança e tolerabilidade da retirada de 
furosemida em pacientes ambulatoriais com Insuficiência Cardíaca crônica estável: 
estudo ReBIC-1 
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ABSTRACT 
Aims. Furosemide is commonly prescribed for symptom relief in heart failure (HF) patients. 
Although few data support the continuous use of loop diuretics in apparently euvolemic HF 
patients with mild symptoms, there are concerns about safety of diuretic withdraw in these 
patients. The ReBIC-1 trial was designed to evaluate the safety and tolerability of withdrawing 
furosemide in stable, euvolemic, chronic HF outpatients. This multicenter initiative is part of a 
Brazilian Research Network in Heart Failure (ReBIC) created to develop clinical studies in HF 
and composed predominantly by university tertiary care hospitals. 
Methods. The ReBIC-1 trial is currently enrolling HF patients in NYHA functional class I-II, 
left ventricular ejection fraction ≤ 45%, without a HF-related hospital admission within the last 
6 months, receiving a stable dose of furosemide (40 or 80 mg per day) for at least 6 months. 
Eligible patients will be randomized to maintain or withdraw furosemide in a double-blinded 
protocol. The trial has two co-primary outcomes: (1) dyspnea assessment using a visual-
analogue scale evaluated at 4 time points and (2) the proportion of patients maintained without 
diuretics at the final visit. Enrolled patients will be followed up to 90 days after randomization, 
and diuretic will be restarted if clinical deterioration or signs of congestion are detected. Pre-
defined sub-group analysis based on NT-pro-BNP levels at baseline is planned. 
Perspective. Evidence-based strategies aiming to simplify HF pharmacotherapy are needed in 
clinical practice. The ReBIC-1 trial will determine the safety of withdrawing furosemide in 
stable chronic HF patients.  
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INTRODUCTION 
 
Drug therapy for heart failure (HF) has greatly improved in the last 4 decades, impacting 
in HF-related morbidity and mortality (1). These unquestionable advances, however, were 
coupled with the hurdles of polypharmacy, the complexity of multiple therapeutic regimens and 
the inconvenience of potential side effects. Strategies aiming to simplify HF pharmacotherapy 
are currently the focus of clinical research (2). 
Diuretics play a central role in HF treatment, mainly during episodes of acute 
decompensation (3). Furosemide is the prototype of loop diuretics, acting through the inhibition 
of the Na+K+2Cl- pump at the thick ascending limb of the Henle loop. According to the 
ADHERE, the EuroHeart Failure Survey and the BREATHE registries, most patients receive a 
loop diuretic during a hospital stay for acute decompensated HF and the majority is discharged 
taking a “maintenance dose” (4-6). Despite the undeniable beneficial hemodynamic effects 
leading to improvement of peripheral and central congestion, the net clinical effect of the 
chronic use of diuretics on HF prognosis is controversial.  
Observational studies suggest that use of high doses of diuretics might be related to 
unfavorable clinical consequences, with a dose dependent association with impaired survival 
(7,8). Few prospective clinical studies, however, directly evaluated the clinical risks and benefits 
of diuretic use (9,10). Recently, a meta-analysis, published in 2012, of 14 small randomized 
controlled trials suggesting that diuretics might reduce the risk of death and HF worsening has 
been withdrawn due to methodological problems (11). 
Current clinical guidelines are unanimous to recommend use of diuretics in HF patients 
with clinical signs and symptoms of congestion, but reinforce the lack of solid clinical scientific 
evidence for its use, and the potential risks that might be involved (12-14). The European 
Society of Cardiology proposes the administration of the lowest dose necessary to achieve 
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euvolemia, avoiding the unnecessary delay in the use of drugs that modify the natural history of 
the disease (14). However, in clinical practice, concerns about worsening symptoms and 
congestion limit furosemide withdrawing.  
Based on these uncertainties about diuretic use in HF, the ReBIC-1 trial was designed to 
evaluate the safety and tolerability of withdrawing furosemide use in stable, euvolemic, chronic 
HF outpatients in a multicenter double-blinded randomized clinical trial. 
 
METHODS 
 
Methods 
ReBIC is a Brazilian research network created to develop clinical studies in heart failure 
and composed predominantly by university tertiary care hospitals. Data collection, 
management, and analysis will be performed at the network’s data coordinating center at 
Hospital de Clínicas de Porto Alegre. All the authors reviewed and approved the manuscript and 
assume full responsibility for the accuracy and completeness of the data and for the fidelity of 
this report of the study protocol. 
 
Study design 
ReBIC-1 is a randomized, double-blinded, parallel group, placebo-controlled, two-arm 
trial comparing the short-term safety and tolerabitlity of discontinuation of furosemide in 
apparently euvolemic outpatients with chronic stable HF and reduced left ventricular ejection 
fraction. 
 
Recruitment and enrollment 
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 Eligible patients on the clinics of Heart Failure from tertiary hospitals in Brazil are 
phone contacted to evaluation at a screening visit. Patients are men and women between the 
ages of 18 and 80 years. 
The ReBIC-1 trial is enrolling HF outpatients that fulfill the following criteria:     
(1) NYHA functional class I or II;  
(2) LVEF ≤ 45% by transthoracic two-dimensional echocardiography performed 
within12 months before the screening visit; 
(3) no previous HF related hospitalization or visit to emergency room within 6 months 
before the screening visit;  
(4) treatment with a stable dose of furosemide (40 or 80 mg per day) for at least 6 months 
before the screening visit;  
(5) serum potassium < 5 mEq/L;  
(6) optimal HF treatment with angiotensin converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARB) and beta-blockers, unless contraindicated or not 
tolerated. Patients receiving mineralocorticoids receptors antagonist or thyazides were 
included at study. We do not relate patients receiving Angiotensin II Receptor Blocker 
Neprilysin Inhibitor (ARNI) because that is not avaliable in Brasil. 
Factors that would have resulted in exclusion include: (1) clinical congestion score 
(CCS) > 5 points (supplementary Table 1); (2) prior acute coronary syndrome, stroke or 
myocardial revascularization within 3 months before the screening visit; (3) any severe valve 
heart disease (aortic, mitral or tricuspid); (4) severe pulmonary disease (asthma, emphysema or 
fibrosis); (5) severe hepatic failure or cirrhosis; (6) end-stage acute or chronic renal disease (on 
hemodialysis); (7) malignancy on active treatment; (8) congenital heart disease; (9) participation 
on any other interventional clinical research; (10) inability to understand and sign the informed 
consent. During follow-up up titration of cardiovascular drugs was discouraged. 
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Sample size on study power 
On the basis of our initial power calculation we estimate that 230 patients would need to 
undergo randomization to have 80% power to detect a 600 points difference between groups in 
the AUC of dyspnea visual analogue scale and a power of 80% to detect a difference of 15% in 
the need to furosemide during the 90 days follow-up. We considered a 600 points difference to 
be a reasonable estimate of the minimum clinically important variation to this scale. 
All analyses will be performed according to the intention-to-treat principle. Owing to 
the use of two coprimary end points (an efficacy, the feasibility of furosemide withdraw, and a 
safety end point measured by dyspnea VAS), the prespecified threshold for significance for each 
end point is a p value of less than 0.05. 
For secondary end points, a p value of less than 0.05 will be considered to indicate 
statistical significance. The discontinuation furosemide group will compare with the use of a 
linear model (for continuous end points, logistic regression for binary end points, or a Cox model 
and Kaplan-Meier curves for time-to-event end points). In the case of end points for which a 
relevant baseline value was measured (6 minute walking test and NT-proBNP) the analysis will 
also be adjusted for the baseline value of that measure. 
The change in the Clinical Congestion Score will be evaluated with a repeated measures 
analysis. Adverse events will be compared with the use of Fisher’s exact test; prospectively 
defined adverse events of interest included weight gain, renal impairment and hyperkalemia. 
All P values are two-sided. 
 
Ethics and informed consent 
Approval of the study protocol was provided by the medical ethics committee of the 
coordinating center Hospital de Clínicas de Porto Alegre and approved at each participating 
center. Patients give written informed consent after receiving detailed written and oral 
information about the study. 
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Random and allocation 
Participants will be randomly allocated in a 1:1 ratio to either an intervention 
(withdrawal of furosemide) or control (maintenance of furosemide) arm. Randomization will be 
computer generated and stratified by center and diuretic dose to facilitate balance between the 
two treatment arms. We estimate that approximate 30% of the sample will be using 80 mg of 
furosemide, according to our clinics patients.  
Intervention 
After the initial clinical and laboratory assessment to evaluate inclusion and exclusion 
criteria, HF outpatients will be randomized to receive placebo or to continue receiving 
furosemide at their usual dose (40 or 80mg/day) for three months, while the background HF 
therapy will remain unchanged. Both patients and researchers will be blinded to group 
allocation. Patients will receive 2 identical bottles of research pills at each visit: a bottle of 
morning pills to be ingested at 8:00 AM and a bottle of afternoon pills to be ingested at 2:00 
PM. Therefore, subjects previously taking 40 mg of furosemide will receive two bottles of 
placebo (withdrawal group) or one bottle of furosemide and one bottle of placebo (maintenance 
group). Subjects previously taking 80 mg of furosemide will receive two bottles of placebo 
(withdrawal group) or two bottles of furosemide (maintenance group).  
 
Follow-up period 
 
Visit 1 
At visit 1, patient eligibility will be assessed according to the above-mentioned criteria. 
Data regarding HF diagnosis, clinical comorbidities, physical examination (to assess the clinical 
congestion score [CCS]) (15), and laboratory results will be reviewed by a clinical cardiologist. 
Once eligibility is confirmed and the informed consent form is signed, subjects will undergo a 
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standard 6 minute-walk test (16) and will be asked to self-assess their level of dyspnea using a 
visual analog scale (VAS) method (see below - study objectives). At visit 1, blood will also be 
drawn to measure NT-pro-BNP levels using total heparinized venous blood and a point-of-care 
equipment (COBAS h 232, measuring range from 60-9000 pg/mL; F. Hoffmann-La Roche Ltd, 
Basel, Swiss). After randomization, patients will then receive 2 bottles (20-25 pills per bottle) 
of the study drug (morning [8AM] and afternoon [14PM] pills) in a blinded fashion. 
 
Visit 2  
Patients will be assessed 15 days after randomization to assure safety and tolerability of 
study drugs. During visit 2, research personnel will (1) review data regarding signs and 
symptoms of HF worsening, (2) calculate the CCS, (3) apply the VAS to reassess the dyspnea 
level, and (4) count the remaining pills in the supplied bottles. Adverse events, tolerability and 
need of additional furosemide will be evaluated, according to pre-defined criteria. Clinical 
events (emergency department visits or hospital admissions) will be evaluated for future 
adjudication. Patients will receive 2 additional bottles (35-40 pills per bottle) of the study drug 
(morning [8AM] and afternoon [14PM] pills) in a blinded fashion. 
 
Visit 3  
Visit 3 will be performed approximately 45 days after randomization. In addition to all 
procedures executed during visit 2, subjects will also reassess routine laboratory exams and NT-
pro-BNP levels. Patients will receive 2 additional bottles (50-55 pills per bottle) of the study 
drug (morning [8AM] and afternoon [14PM] pills) in a blinded fashion. 
 
Visit 4  
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Visit 4 will be performed approximately 90 days after randomization. In addition to all 
procedures executed during visit 3, subjects will also undergo a final 6 minute-walk test. At the 
final visit, patients will be oriented to reassume their baseline furosemide regimen, irrespective 
of the clinical outcome during the protocol.  
 
Study Objectives – Primary and secondary endpoints 
 The trial will have two co-primary endpoints to evaluate the feasibility of furosemide 
withdrawal. First, dyspnea will be assessed using a visual-analogue scale (VAS). Patients will 
be asked to mark their level of dyspnea on a horizontal line based on their sensation of shortness 
of breath during the last week. The left side of the line will indicate “I am not breathless at all” 
and the right side will indicate “severe breathless”. The VAS will be scored from 0 to 100 
(subjects will be unaware of the numerical value of their response), and applied at baseline, day 
15, day 45 and day 90 after randomization. The area under the curve (AUC) of serial assessments 
of the dyspnea VAS from baseline to the end of follow-up will be the first co-primary efficacy 
endpoint. The second co-primary endpoint will be the percentage of patients maintained without 
loop diuretics by the end of follow-up (90 days). 
The ReBIC-1 will have 5 secondary endpoints: 
(1) the variation on NT pro-BNP levels measured at baseline, day 45 and  final visit;  
(2) the variation in meters in the 6-minute walk test (baseline to final visit); 
(3) the variation in the glomerular filtration rate (ml/min/1.73 m²)  estimated by the 
Modification of Diet in Renal Disease equation (MDRD)  at baseline, day 45 and final visit; 
(4) the percentage of patients with a CCS > 5 points at the final visit;  
(5) a composite clinical endpoint of heart failure-related death,  hospitalization, or 
emergency room visit during follow-up. 
(6) Six-minute-walking test at baseline at final visit. 
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The ReBIC-1 trial will have only one pre-specified sub-group analysis based on the 
baseline levels of NT pro-BNP (median and a pre-specified value of 600 pg/mL).  
Criteria for initiation of loop diuretic during follow-up 
 Use of loop diuretics during study visits will be decided by a physician blinded to group 
allocation, according to pre-defined clinical criteria. It will be recommended the reuse of loop 
diuretics if a patient has a clear clinical evidence of worsening of congestion (increases in the 
CCS > 5 points and increases in weight > 2 Kg along with new symptoms or increase in NYHA 
functional class). The patients with worse of clinical status will be oriented to stop study 
medication and returned to your usual dose of furosemide. All patients will be followed until 
the end of 90 days’ follow-up, besides need to stop study intervention and reintroduce 
furosemide. The attendant physician judge to enhance diuretic dose after reintroduce furosemide 
that will be allowed. Variations in NT pro-BNP levels will not be used as an index of clinical 
congestion.  
 
Endpoints adjudication 
 Classification of clinical outcomes will be performed by an independent committee 
(composed of 3 researchers separately and blinded for group allocation), based on review of 
data and forms collected by research personnel, hospital charts and death certificate (when 
appropriate). Eventual discordant cases will be defined by consensus. 
 
Data analysis 
 
Current Status 
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In order to recruit the 238 patients, all tertiary hospitals and HF clinics invited to this 
study, have agreed to participate in this research. The first patient was included in September 
2015 and on March 24th 2017, the study has randomized 94 patients at 6 centers in Brazil. 
Recruitment is expected to be completed by December 2017 and the study should close at the 
beginning of 2018. To guide this study, a scientific advisory board was established with the 
main goal to advise the participants centres with regard to issues on data collection and follow-
up vistis. Members included in the scientific advisory board are the principle investigator and 2 
cardiologists and one nurse. The study is being conducted in accordance with the "Good Clinical 
Practice" recommendations, based on the Declaration of Helsinki (2002). The trial has been 
registered on Clinicaltrials.gov, NCT02689180 
DISCUSSION 
 REBIC-1 is a randomized, double-blinded, multicenter trial that will provide important 
information about the safety and tolerability of diuretic withdrawing in euvolemic outpatients 
with HF.  Physicians that treat chronic HF are frequently faced with the clinical dilemma of 
maintaining furosemide, a drug that has been associated with serious side effects and a worse 
prognosis, or withdrawing it, at the risk of worsen congestive symptoms and overall morbidity. 
So far, data has been conflicting and methodologically limited to help in this decision.  
 Observational studies have consistently suggested that chronic use of diuretics might be 
deleterious. A cohort study of HF patients with left ventricular systolic dysfunction observed a 
dose-dependent association between loop diuretic use and impaired survival, after extensive 
covariate adjustment, particularly for patients using high-dose furosemide (7). In 813 
consecutive outpatients with chronic HF, the risk of death increased linearly across quartiles of 
furosemide daily dose after stratification for a propensity score. A threshold dose of 50 mg/day 
was related with worse clinical outcomes (8). Domanski et al demonstrated that the risk of 
hospitalization or death due to worsening HF in patients taking non-potassium sparing diuretics 
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was significantly increased by 31% compared with patients not taking any diuretic in a sub-
analysis of the SOLVD trial (17). Undesirable side effects of loop diuretics are also not trivial 
and involve activation of the renin-angiotensin-aldosterone system, elevation of norepinephrine 
levels, increases in heart rate, detrimental effects on renal function and several electrolyte 
disturbances (3-7). 
 
 Few interventional studies have been conducted to evaluate the effects of adjusting 
diuretic doses in HF patients. The Dose Trial (3) shed some light in the strategies of diuretic 
adjustment in the scenario of acute decompensated HF, but there is scarce data in the outpatient 
setting. Three decades ago, Cowley et al suggested that a strategy based on increasing 
furosemide dose might have more favorable effects on exercise tolerance in symptomatic HF 
patients than an approach based on adding captopril (9). Richardson et al directly tested the 
substitution of furosemide by captopril in 14 symptomatic HF patients in a randomized 
crossover clinical trial. Most patients tolerated the switch, but some developed severe 
pulmonary congestion (10). In an uncontrolled study, McKie et al (18) evaluated the effects of 
furosemide reduction in 32 patients with stable symptomatic HF (NYHA class II-III) with and 
without underlying renal dysfunction. They concluded it was safe to reduce diuretics, a strategy 
that improved renal function in some subjects, without changes in volume or functional status. 
Recently, 40 chronic HF patients using ≥ 120 mg of furosemide/day were randomized to either 
continuation or reduction of furosemide doses in tertiary university medical center in Greece. 
Decrease of diuretic dose was tolerated in most patients without further cardiac decompensation 
and was associated with a tendency towards a better prognosis (19). Although provocative, both 
studies that assessed strategies of diuretic reduction evaluated patients taking higher doses of 
furosemide than those that will be enrolled in the ReBIC-1 trial. This subgroup might not be 
representative of most HF outpatients, as stable patients usually take lower doses of furosemide 
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(20). In addition, most available data on diuretic adjustment in HF outpatients is derived from 
small single center reports, without an adequate control group or blinding of interventions, and 
most protocols are not adequately powered to allow conclusions with broad clinical 
applicability.  
 Recent HF guidelines from the European Society of Cardiology state that diuretics might 
be discontinued in selected asymptomatic euvolemic or hypovolemic patients (14). However, 
identification of this scenario is challenging in clinical practice and the safety of this strategy is 
uncertain. In this regard, the pre-specified stratified analysis based on natriuretic peptide levels 
planned by the ReBIC-1 trial may help to identify patients that might not be eligible to diuretic 
discontinuation. Evaluation of dyspnea, clinical congestion, functional status, and natriuretic 
peptide levels will be performed in order to assure clinical stability during follow-up visits. The 
ReBIC-1 trial will be the first multicenter, double-blind, randomized study to address different 
diuretic adjustment strategies in outpatients with stable HF due to left ventricular dysfunction. 
Limitations 
Bias was carefully avoided throughout the trial. Selection bias was avoided by having 
an independent researcher randomize the participants after the baseline data had been 
collected. Detection bias was avoided by having the follow-up data collected by a researcher 
who was not involved in randomization. Conclusions 
 If proven safe and feasible in the present study, diuretic withdraw might be considered 
as part of the evidence-based approaches in the context of chronic HF, potentially simplifying 
HF therapy and reducing adverse effects in euvolemic ambulatory patients. 
 
Disclosures 
The authors are solely responsible for the design and conduct of this study, all study analyses, 
the drafting and editing of the paper, and its final contents. 
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Figure Legends 
Figure 1. Flow diagram 
Table Legends 
Table1. Recruitment centers and respective principal investigator. 
 
 
 
Figure 1. 
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Institution Primary Investigators Status 
Initiation of 
Randomization 
The ReBIC Coordinator Center: Hospital de Clinicas de Porto Alegre 
Principal Investigators: Luis E. Rohde, MD and Andréia Biolo, MD 
Research Coordinators: Priscila Raupp da Rosa, MD and Madeni Doebber, RN 
Hospital de Clinicas de Porto Alegre Andréia Biolo, MD Recruiting Yes 
Hospital Universitário da ULBRA/RS Luiz Cláudio Danzmann, MD Recruiting Yes 
Instituto de Cardiologia – IC/FUC RS Marciane Rover, MD Recruiting Yes 
Hospital Universitário da UFPEL/RS Eduardo Gehling Bertoldi, MD Recruiting Yes 
Hospital São Lucas da PUC/RS Priscila Raupp da Rosa, MD Recruiting Yes 
Hospital Moinhos de Vento – RS Luis Beck-da-Silva, MD Approved No 
Hospital da PUC/PR Lidia Moura Zytynski, MD Recruiting Yes 
Hospital Universitário UFMA Jose Albuquerque Figueiredo Neto, MD Recruiting Yes 
Hospital de Clinicas da UFMG Antonio Luiz Pinho Ribeiro, MD Recruiting Yes 
Hospital IGESP da UNIFESP Dirceu Rodrigues de Almeida, MD Submitted No 
 
Table 1. 
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Supplementary  
Table 1. Clinical congestion Score. 
CLINICAL CONGESTION SCORE 
FUNCTIONAL CLASS 
NYHA I 1 point 
NYHA II 2points 
NYHA III 3points 
NYHA IV 4points 
ORTHOPNEIA and PAROXYSMAL NOCTURNAL DYSPNEA (PND) 
One pillow to sleep 0 points 
> 1 pillow to sleep 1 point 
At least 1 episode of PND last week 2 points 
Several  episodes of PND last week 3 points 
Slept  sitting at least once last week 4 points 
EDEMA 
No edema 0 points 
Edema 1/4+ 1 point 
Edema 2/4+ 2 points 
Edema 3/4+ 3 points 
Edema 4/4+ 4 points 
RALES 
No rales 0 points 
Basal rales (< ¼ of posterior lungs) 1 point 
Rales  from ¼ to ½ of posterior lungs 2 points 
Rales> ½ of posterior lungs 3 points 
Rales in all lung fields (anterior and posterior) 4 points 
S3 
YES  1 point 
HEPATOJUGULAR REFLUX 
YES 1 point 
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ESTIMATED CENTRAL VENOUS PRESSURE (CVP) 
CVP:not measureable 0 points 
CVP between 5-8 cm H2O 1 point 
CVP between 8-12 cm H2O 2 points 
CVP between 12-15 cm H2O 3 points 
CVP between > 15 cm H2O 4 points 
FINAL SCORE 
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8.1 REBIC 1 – DADOS PRELIMINARES  
  
O estudo está em andamento em 9 hospitais terciários, com o primeiro paciente 
randomizado em novembro de 2015, totalizando 94 pacientes incluídos e 62 pacientes 
com seguimento completo. Dados preliminares de 87 pacientes mostram, dentre as  
características da amostra, o predomínio de homens caucasianos com idade média 60,1 
anos, hipertensos na sua maioria e diabéticos. As etiologias isquêmica e idiopática são as 
principais nesses pacientes (32% e 28%, respectivamente) com fração de ejeção média 
32,5%. Dentre as medicações, todos estavam em uso de betabloqueador e 95% em uso 
inibidor da ECA ou bloqueador do receptor da angiotensina (BRA).  A creatinina média 
foi de 1,12 mg/dL e apenas 16 pacientes possuíam algum tipo de dispositivo cardíaco 
(Tabela 1). 
Com perspectiva de término do estudo, em 2017, com 230 pacientes 
randomizados pretende-se esclarecer se a retirada de diurético em pacientes crônicos é 
factível e avaliar quais são os preditores de sucesso desta conduta. 
Tabela 1 
CARACTERÍSTICAS DA AMOSTRA  
Sexo masculino (n,%) 63 (73) 
Etnia caucasiana (n,%) 61 (70) 
Idade, anos (média) 60,1 
IMC (média) 28,3 
PAS, mmHg (média) 124 
PAD, mmHg (média) 76 
Frequência cardíaca, bpm (média) 69 
FE, % 32 
Teste de caminhada, m 367 
EAV da dispneia, mm 36 
NT-proBNP ng/dL 1.118 
Creatinina, mg/dL 1,12 
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COMORBIDADES 
Hipertensão arterial (n,%) 51 (62) 
Diabetes mellitus (n,%) 28 (34) 
História de tabagismo (n,%) 35 (40) 
Fibrilação/flutter atrial (n,%) 13 (15) 
AVE prévio 6 (7) 
Hipotireoidismo (n,%) 5 (6) 
Dispositivos (n,%) 11 (18) 
CLASSE FUNCIONAL 
NYHA I (n,%) 64 (73) 
NYHA II (n,%) 23 (26) 
ETIOLOGIA 
Isquêmica (n,%) 28 (32) 
Idiopática (n,%) 25 (28) 
Hipertensiva (n,%) 19 (21) 
Valvular (n,%) 3 (3,4) 
Peri parto (n,%) 2 (2,3) 
Chagásica (n,%) 2 (2,3) 
Pós-quimioterapia (n,%) 1 (1,4) 
Alcoólica (n,%) 2 (2,3) 
TRATAMENTO 
Betabloqueadores (n,%) 86 (100) 
       Tartarato de metoprolol (n,%) 39 (44) 
       Carvedilol (n,%) 32 (36) 
       Succinato de metoprolol (n,%) 10 (11) 
       Bisoprolol (n,%) 4 (4,5) 
BRA (n,%) 29 (33) 
IECA (n,%) 54 (62) 
       Enalapril (n,%) 47 (54) 
       Captopril (n,%) 31 (35) 
       Lisinopril (n,%) 3 (3,4) 
Espironolactona (n,%) 64 (73) 
Digoxina (n,%) 38 (43) 
AAS (n,%) 37 (42) 
Hidralazina (n,%) 16 (18) 
Nitrato(n,%) 15 (17) 
Tiazídicos (n,%) 7 (8) 
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9. CONCLUSÕES E CONSIDERAÇÕES FINAIS 
 
A realização dos projetos descritos nesta tese agrega resultados de grande 
importância para o conhecimento da insuficiência cardíaca. Nossa metanálise sobre o 
efeito do sildenafil relacionado com o tempo demonstra que os dados de estudos de 
intervenção em humanos mostram um significante benefício hemodinâmico em 
remodelamento e, principalmente, na redução do número de hospitalizações. Embora um 
estudo de metanálise tenha um elevado nível de evidência, sugere-se a realização de 
ensaio clínico multicêntrico com pacientes com disfunção ventricular para confirmar o 
benefício da droga e acrescentá-la nas diretrizes de insuficiência cardíaca. 
Quanto às conclusões dos estudos com diuréticos, podemos afirmar que as 
evidências disponíveis para indicação de diurético de alça em pacientes com insuficiência 
cardíaca crônica em classes funcionais NYHA I-III são fracas e insuficientes para 
embasamento de uma recomendação. Sendo assim, a prática atual relacionadas à 
prescrição de diurético de alça deve ser revista à luz de novas evidências. 
Confiamos que os resultados do estudo ReBIC 1 contribuirá para a construção do 
conhecimento nesta área. O estudo REBIC-1 está com aproximadamente 100 pacientes 
randomizados até o momento e temos a pretensão de finalizar as inclusões até dezembro 
de 2017. 
Independentemente dos futuros resultados do estudo ReBIC 1, a iniciativa para a 
implementação da Rede Brasileira de Insuficiência Cardíaca, integrando clínicas 
especializadas em IC de hospitais terciários é a principal meta e legado deste estudo. Pela 
primeira vez no Brasil, temos um projeto que integra cardiologistas, que são expoentes 
no tratamento de ponta de IC num esforço voltado para o cuidado do paciente crônico 
ambulatorial ou manejado na atenção primária. 
111 
 
 
 
 
